APOE and atherosclerosis: Moreover, AVE 0991 is a nonpeptide and orally active angiotensin-(1–7) receptor agonist with an IC50 of 21 nm that was also shown to exhibit anti-atherosclerotic and anti-inflammatory actions; affecting monocyte/macrophage differentiation and recruitment to perivascular space during early stages of atherosclerosis in ApoE−/− mice.